RT Journal Article
SR Electronic
T1 Antibody responses to SARS-CoV-2 train machine learning to assign likelihood of past infection during virus emergence in Sweden
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.17.20155937
DO 10.1101/2020.07.17.20155937
A1 Dopico, Xaquín Castro
A1 Hanke, Leo
A1 Sheward, Daniel J.
A1 Muschiol, Sandra
A1 Aleman, Soo
A1 Christian, Murray
A1 Grinberg, Nastasiya F.
A1 Adori, Monika
A1 Vidakovics, Laura Perez
A1 Kim, ChangIl
A1 Khoenkhoen, Sharesta
A1 Pushparaj, Pradeepa
A1 Morro, Ainhoa Moliner
A1 Mandolesi, Marco
A1 Ahl, Marcus
A1 Forsell, Mattias
A1 Coquet, Jonathan
A1 Corcoran, Martin
A1 Rorbach, Joanna
A1 Dillner, Joakim
A1 Bogdanovic, Gordana
A1 McInerney, Gerald
A1 Allander, Tobias
A1 Wallace, Chris
A1 Murrell, Ben
A1 Albert, Jan
A1 Karlsson Hedestam, Gunilla B.
YR 2020
UL http://medrxiv.org/content/early/2020/10/19/2020.07.17.20155937.abstract
AB Serology is critical for understanding pathogen-specific immune responses, but is fraught with difficulty, not least because the strength of antibody (Ab) response varies greatly between individuals and mild infections generally generate lower Ab titers1–3. We used robust IgM, IgG and IgA Ab tests to evaluate anti-SARS-CoV-2 responses in individuals PCR+ for virus RNA (n=105) representing different categories of disease severity, including mild cases. All PCR+ individuals in the study became IgG-positive against pre-fusion trimers of the virus spike (S) glycoprotein, but titers varied greatly. Elevated IgA, IL-6 and neutralizing responses were present in intensive care patients. Additionally, blood donors and pregnant women (n=2,900) sampled throughout the first wave of the pandemic in Stockholm, Sweden, further demonstrated that anti-S IgG titers differed several orders of magnitude between individuals, with an increase of low titer values present in the population at later time points4,5. To improve upon current methods to identify low titers and extend the utility of individual measures6,7, we used our PCR+ individual data to train machine learning algorithms to assign likelihood of past infection. Using these tools that assigned probability to individual responses against S and the receptor binding domain (RBD), we report SARS-CoV-2-specific IgG in 13.7% of healthy donors five months after the peak of spring COVID-19 deaths, when mortality and ICU occupancy in the country due to the virus were at low levels. These data further our understanding of antibody responses to the virus and provide solutions to problems in serology data analysis.Significance statement Antibody testing provides critical clinical and epidemiological information during an emerging disease pandemic. We developed robust SARS-CoV-2 IgM, IgG and IgA antibody tests and profiled COVID-19 patients and exposed individuals throughout the outbreak in Stockholm, Sweden, where full societal lockdown was not employed. As well as elucidating several disease immunophenotypes, our data highlight the challenge of identifying low IgG titer individuals, who comprise a significant proportion of the population following mild/asymptomatic infection, especially as antibody titers wane following peak responses. To provide a solution to this, we used SARS-CoV-2 PCR+ individual data to develop machine learning approaches that assigned likelihood of past infection to blood donors and pregnant women, improving the accuracy and utility of individual and population-level Ab measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this work was provided by a Distinguished Professor grant from the Swedish Research Council (agreement 532 2017-00968) and NIH (agreement SUM1A44462-02). CW and NFG are funded by the Wellcome Trust (WT107881) and MRC (MC_UP_1302/5)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Swedish Ethical Review Authority (registration no. 2020-01807).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData generated as part of the study, along with custom code for statistical analyses, is openly available via our GitHub repositories: https://github.com/MurrellGroup/DiscriminativeSeroprevalence/ and https://github.com/chr1swallace/seroprevalence-paper.